Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/selective-mmp13-inhibitors-in3Rd0zffk
References (91)
-
K. Freeman-Cook, L. Reiter, M. Noe, A. Antipas, D. Danley, K. Datta, J. Downs, S. Eisenbeis, J. Eskra, David Garmene, Elaine Greer, R. Griffiths, Roberto Guzman, Joel Hardink, F. Janat, Christopher Jones, G. Martinelli, P. Mitchell, E. Laird, J. Liras, L. Lopresti-Morrow, J. Pandit, Usa Reilly, D. Robertson, Marcie Vaughn-Bowser, Lilli Wolf-Gouviea, S. Yocum (2007)
Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.Bioorganic & medicinal chemistry letters, 17 23
-
A. Johnson, A. Pavlovsky, D. Ortwine, F. Prior, C. Man, D. Bornemeier, C. Banotai, W. Mueller, P. McConnell, Chunhong Yan, V. Baragi, C. Lesch, W. Roark, Michael Wilson, K. Datta, Roberto Guzman, Hyo-Kyung Han, R. Dyer (2007)
Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects*Journal of Biological Chemistry, 282
-
P. Mitchell, H. Magna, L. Reeves, L. Lopresti-Morrow, S. Yocum, P. Rosner, K. Geoghegan, J. Hambor (1996)
Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.The Journal of clinical investigation, 97 3
-
H. Welgus, D. Kobayashi, J. Jeffrey (1983)
The collagen substrate specificity of rat uterus collagenase.The Journal of biological chemistry, 258 23
-
E. Breuer, Julia Frant, R. Reich (2005)
Recent non-hydroxamate matrix metalloproteinase inhibitorsExpert Opinion on Therapeutic Patents, 15
-
(2000)
WO0044709 WO0044711 WO0044749 (2000 American Cyanamid) -
James Chen, Nelson Christy, J. Levin, D. Mobilio, F. Moy, R. Nilakantan, A. Zask, R. Powers (2000)
Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular designJournal of the American Chemical Society, 122
-
P. Hajduk, G. Sheppard, D. Nettesheim, E. Olejniczak, S. Shuker, R. Meadows, D. Steinman, G. Carrera, P. Marcotte, Jean Severin, K. Walter, Harriet Smith, E. Gubbins, R. Simmer, T. Holzman, D. Morgan, S. Davidsen, Andrey Summers, S. Fesik (1997)
Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMRJournal of the American Chemical Society, 119
-
M. Noe, Vijayalakshmi Natarajan, Sheri Snow, Lilli Wolf-Gouveia, P. Mitchell, L. Lopresti-Morrow, L. Reeves, S. Yocum, I. Otterness, Marcia Bliven, T. Carty, John Barberia, F. Sweeney, J. Liras, Marcie Vaughn (2005)
Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.Bioorganic & medicinal chemistry letters, 15 14
-
J. Levin, J. Chen, M. Du, F. Nelson, T. Wehr, J. Dijoseph, L. Killar, S. Skala, A. Sung, M. Sharr, C. Roth, G. Jin, R. Cowling, L. Di, M. Sherman, Z. Xu, C. March, K. Mohler, R. Black, J. Skotnicki (2001)
The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.Bioorganic & medicinal chemistry letters, 11 22
-
Janelle Lauer-Fields, D. Minond, Peter Chase, Pierre Baillargeon, S. Saldanha, Roma Stawikowska, P. Hodder, G. Fields (2009)
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.Bioorganic & medicinal chemistry, 17 3
-
M. Letavic, John Barberia, T. Carty, Joel Hardink, J. Liras, L. Lopresti-Morrow, P. Mitchell, M. Noe, L. Reeves, Sheri Snow, E. Stam, F. Sweeney, Marcie Vaughn, Chul Yu (2003)
Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.Bioorganic & medicinal chemistry letters, 13 19
-
(2007)
After a stint at MIT as a postdoctoral fellow, he worked at Parke-Davis Pharmaceuticals from 1997 to 2000 and then from 2000 to 2007 after Parke-Davis was acquired by Pfizer -
J. Levin (2001)
Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.Bioorganic & medicinal chemistry letters, 11 2
-
(2004)
Pyrimidine-4,6dicarboxylic acid diamides for use as selective MMP13 inhibitors. International Patent Application WO2004/060883 (2004 Aventis) -
D. Shalinsky, John Brekken, H. Zou, Charles McDermott, P. Forsyth, D. Edwards, S. Margosiak, S. Bender, G. Truitt, Alexandra Wood, N. Varki, K. Appelt (1999)
Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical TrialsAnnals of the New York Academy of Sciences, 878
-
J. Freije, I. Diez-Itza, M. Balbín, Luis Sánchez, Rafael Blasco, Jorge Tolivia, Carlos López-Otín (1994)
Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas.The Journal of biological chemistry, 269 24
-
A. Fosang, C. Little (2008)
Drug Insight: aggrecanases as therapeutic targets for osteoarthritisNature Clinical Practice Rheumatology, 4
-
J. Blagg, M. Noe, Lilli Wolf-Gouveia, L. Reiter, E. Laird, Shang-Poa Chang, D. Danley, J. Downs, N. Elliott, J. Eskra, R. Griffiths, Joel Hardink, Amber Haugeto, Christopher Jones, J. Liras, L. Lopresti-Morrow, P. Mitchell, J. Pandit, R. Robinson, C. Subramanyam, Marcie Vaughn-Bowser, S. Yocum (2005)
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.Bioorganic & medicinal chemistry letters, 15 7
-
N. Johansson, U. Saarialho‐kere, K. Airola, R. Herva, L. Nissinen, J. Westermarck, E. Vuorio, J. Heino, V. Kähäri (1997)
Collagenase‐3 (MMP‐13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone developmentDevelopmental Dynamics, 208
-
J. Peterson (2004)
Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug DiscoveryHeart Failure Reviews, 9
-
D. Becker, T. Barta, L. Bedell, G. Decrescenzo, John Freskos, D. Getman, S. Hockerman, Madeleine Li, Pramod Mehta, B. Mischke, G. Munie, Craig Swearingenb, Clara Villamila (2001)
α-Amino-β-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1Bioorganic & Medicinal Chemistry Letters, 11
-
Jennifer Jacobsen, Jody Jourden, Melissa Miller, Seth Cohen (2010)
To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition.Biochimica et biophysica acta, 1803 1
-
H. Welgus, G. Grant, J. Sacchettini, W. Roswit, J. Jeffrey (1985)
The gelatinolytic activity of rat uterus collagenase.The Journal of biological chemistry, 260 25
-
(2003)
Method for identifying metalloenzyme inhibitors -
M. Leeman, J. McKay, G. Murray (2002)
Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancerJournal of Clinical Pathology, 55
-
S. Wojtowicz-Praga, J. Torri, Michael Johnson, V. Steen, J. Marshall, E. Ness, R. Dickson, M. Sale, H. Rasmussen, T. Chiodo, M. Hawkins (1998)
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 6
-
A. Chollet, T. Diguarher, L. Murray, M. Bertrand, G. Tucker, M. Sabatini, A. Pierré, G. Atassi, J. Bonnet, P. Casara (2001)
General Synthesis of α-Substituted 3-Bisaryloxy Propionic Acid Derivatives as Specific MMP Inhibitors.ChemInform, 32
-
J. Levin, J. Chen, L. Laakso, M. Du, J. Schmid, W. Xu, T. Cummons, J. Xu, G. Jin, D. Barone, J. Skotnicki (2006)
Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.Bioorganic & medicinal chemistry letters, 16 6
-
R. Robinson, E. Laird, J. Blake, J. Bordner, K. Donahue, L. Lopresti-Morrow, P. Mitchell, M. Reese, L. Reeves, E. Stam, S. Yocum (2000)
Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.Journal of medicinal chemistry, 43 12
-
(2009)
Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions. International Patent Application -
M. Karsdal, S. Madsen, C. Christiansen, K. Henriksen, A. Fosang, B. Sondergaard (2008)
Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activityArthritis Research & Therapy, 10
-
L. Reiter, P. Mitchell, G. Martinelli, L. Lopresti-Morrow, S. Yocum, J. Eskra (2003)
Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.Bioorganic & medicinal chemistry letters, 13 14
-
D. Wernicke, C. Seyfert, B. Hinzmann, E. Gromnica-ihle (1996)
Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis.The Journal of rheumatology, 23 4
-
G. Murphy, H. Nagase (2008)
Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?Nature Clinical Practice Rheumatology, 4
-
Junjun Wu, T. Rush, R. Hotchandani, Xuemei Du, M. Geck, E. Collins, Z. Xu, J. Skotnicki, J. Levin, F. Lovering (2005)
Identification of potent and selective MMP-13 inhibitors.Bioorganic & medicinal chemistry letters, 15 18
-
N. Hellman, J. Spector, Jonathan Robinson, Xiaofeng Zuo, S. Saunier, C. Antignac, J. Tobias, J. Lipschutz (2008)
Matrix Metalloproteinase 13 (MMP13) and Tissue Inhibitor of Matrix Metalloproteinase 1 (TIMP1), Regulated by the MAPK Pathway, Are Both Necessary for Madin-Darby Canine Kidney Tubulogenesis*Journal of Biological Chemistry, 283
-
A. Jüngel, C. Ospelt, M. Lesch, Melissa Thiel, Teresa Sunyer, Olivier Schorr, B. Michel, R. Gay, C. Kolling, C. Flory, Steffen Gay, M. Neidhart (2009)
Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritisAnnals of the Rheumatic Diseases, 69
-
M. Thabet, T. Huizinga (2006)
Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis.Current opinion in investigational drugs, 7 11
-
Jianchang Li, T. Rush, Wei Li, D. DeVincentis, Xuemei Du, Yonghan Hu, J. Thomason, J. Xiang, J. Skotnicki, S. Tam, K. Cunningham, P. Chockalingam, E. Morris, J. Levin (2005)
Synthesis and SAR of highly selective MMP-13 inhibitors.Bioorganic & medicinal chemistry letters, 15 22
-
M. Noe, Vijayalakshmi Natarajan, Sheri Snow, P. Mitchell, L. Lopresti-Morrow, L. Reeves, S. Yocum, T. Carty, J. Barberia, F. Sweeney, J. Liras, Marcie Vaughn, Joel Hardink, J. Hawkins, C. Tokar (2005)
Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.Bioorganic & medicinal chemistry letters, 15 11
-
(2000)
Novel cyclic N-hydroxamic acid inhibitors of TNF-α synthesis and MMP-13Expert Opinion on Therapeutic Patents, 10
-
T. Etoh, H. Inoue, Y. Yoshikawa, G. Barnard, S. Kitano, Masaki Mori (2000)
Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressivenessGut, 47
-
J. Levin, M. Du, J. Dijoseph, L. Killar, A. Sung, T. Walter, M. Sharr, C. Roth, F. Moy, R. Powers, G. Jin, R. Cowling, J. Skotnicki (2001)
The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.Bioorganic & medicinal chemistry letters, 11 2
-
Soong-Hoon Kim, A. Pudzianowski, Kenneth Leavitt, J. Barbosa, P. McDonnell, W. Metzler, B. Rankin, Richard Liu, Wayne Vaccaro, W. Pitts (2005)
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).Bioorganic & medicinal chemistry letters, 15 4
-
J. Li, J. Nahra, Adam Johnson, A. Bunker, P. O'brien, W. Yue, D. Ortwine, C. Man, V. Baragi, K. Kilgore, R. Dyer, Hyo-Kyung Han (2008)
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.Journal of medicinal chemistry, 51 4
-
M-P. Graverand, Kenneth Brandt, S. Mazzuca, Barry Katz, Robert Buck, Kathleen Lane, E. Pickering, O. Nemirovskiy, T. Sunyer, Dean Welsch (2006)
Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis.Osteoarthritis and cartilage, 14 11
-
L. Reiter, K. Freeman-Cook, Christopher Jones, G. Martinelli, A. Antipas, M. Berliner, K. Datta, J. Downs, J. Eskra, M. Forman, Elaine Greer, Roberto Guzman, Joel Hardink, F. Janat, N. Keene, E. Laird, J. Liras, L. Lopresti-Morrow, P. Mitchell, J. Pandit, D. Robertson, D. Sperger, Marcie Vaughn-Bowser, D. Waller, S. Yocum (2006)
Potent, selective pyrimidinetrione-based inhibitors of MMP-13.Bioorganic & medicinal chemistry letters, 16 22
-
C. Engel, B. Pirard, Sandra Schimanski, R. Kirsch, J. Habermann, O. Klingler, V. Schlotte, K. Weithmann, K. Wendt (2005)
Structural basis for the highly selective inhibition of MMP-13.Chemistry & biology, 12 2
-
D. Stickens, Danielle Behonick, N. Ortéga, B. Heyer, B. Hartenstein, Ying Yu, A. Fosang, Marina Schorpp-Kistner, P. Angel, Z. Werb (2004)
Altered endochondral bone development in matrix metalloproteinase 13-deficient mice, 131
-
J. Levin (2001)
The Discovery of Anthranilic Acid‐Based MMP Inhibitors. Part 2. SAR of the 5‐Position and P11 Groups.ChemInform, 32
-
A. Yiotakis, V. Dive (2008)
Third-Generation MMP Inhibitors: Recent Advances in the Development of Highly Selective Inhibitors -
V. Knäuper, C. López-Otín, Bryan Smith, G. Knight, G. Murphy (1996)
Biochemical Characterization of Human Collagenase-3 (*)The Journal of Biological Chemistry, 271
-
M. Luukkaa, P. Vihinen, P. Kronqvist, T. Vahlberg, S. Pyrhönen, V. Kähäri, R. Grénman (2006)
Association between high collagenase‐3 expression levels and poor prognosis in patients with head and neck cancerHead & Neck, 28
-
L. Reiter, R. Robinson, K. McClure, Christopher Jones, M. Reese, P. Mitchell, I. Otterness, M. Bliven, J. Liras, S. Cortina, K. Donahue, J. Eskra, R. Griffiths, M. Lame, A. Lopez-Anaya, G. Martinelli, S. McGahee, S. Yocum, L. Lopresti-Morrow, Lisa Tobiassen, Marcie Vaughn-Bowser (2004)
Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.Bioorganic & medicinal chemistry letters, 14 13
-
K. Airola, K. Airola, N. Johansson, A. Kariniemi, V. Kähäri, U. Saarialho‐kere, U. Saarialho‐kere (1997)
Human collagenase-3 is expressed in malignant squamous epithelium of the skin.The Journal of investigative dermatology, 109 2
-
E. Olejniczak, P. Hajduk, P. Marcotte, D. Nettesheim, R. Meadows, R. Edalji, T. Holzman, S. Fesik (1997)
Stromelysin Inhibitors Designed from Weakly Bound Fragments: Effects of Linking and CooperativityJournal of the American Chemical Society, 119
-
J. Freskos, J. McDonald, B. Mischke, Patrick Mullins, H. Shieh, R. Stegeman, A. Stevens (1999)
Synthesis and identification of conformationally constrained selective MMP inhibitors.Bioorganic & medicinal chemistry letters, 9 13
-
I. Otterness, K. Brandt, M. Graverand, S. Mazzuca (2007)
Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis: implications of the lack of association between TIINE levels and joint space narrowing.Arthritis and rheumatism, 56 11
-
Bin Zhang, Xuchen Cao, Yanxue Liu, Wenfeng Cao, Fei Zhang, Shiwu Zhang, Hongtao Li, L. Ning, L. Fu, Y. Niu, R. Niu, Baocun Sun, X. Hao (2008)
Tumor-derived Matrix Metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancerBMC Cancer, 8
-
H. Luukkaa, P. Klemi, P. Hirsimäki, T. Vahlberg, A. Kivisaari, V. Kähäri, R. Grénman (2008)
Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancerActa Oto-Laryngologica, 128
-
M. Noe, Sheri Snow, Lilli Wolf-Gouveia, P. Mitchell, L. Lopresti-Morrow, L. Reeves, S. Yocum, J. Liras, Marcie Vaughn (2004)
3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.Bioorganic & medicinal chemistry letters, 14 18
-
R. Robinson, E. Laird, K. Donahue, L. Lopresti-Morrow, P. Mitchell, M. Reese, L. Reeves, A. Rouch, E. Stam, S. Yocum (2001)
Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.Bioorganic & medicinal chemistry letters, 11 9
-
H. Cai, A. Agrawal, D. Putt, M. Hashim, A. Reddy, J. Brodfuehrer, N. Surendran, L. Lash (2009)
Assessment of the renal toxicity of novel anti-inflammatory compounds using cynomolgus monkey and human kidney cells.Toxicology, 258 1
-
Masaki Inada, Yingmin Wang, M. Byrne, Mahboob Rahman, C. Miyaura, C. López-Otín, S. Krane (2004)
Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification.Proceedings of the National Academy of Sciences of the United States of America, 101 49
-
R. Billinghurst, William Wu, M. Ionescu, A. Reiner, L. Dahlberg, Jeffrey Chen, H. Wart, A. Poole (2000)
Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase.Arthritis and rheumatism, 43 3
-
J. Freskos, B. Mischke, G. Decrescenzo, R. Heintz, D. Getman, S. Howard, N. Kishore, J. McDonald, G. Munie, S. Rangwala, C. Swearingen, C. Voliva, D. Welsch (1999)
Discovery of a novel series of selective MMP inhibitors: Identification of the γ-sulfone-thiolsBioorganic & Medicinal Chemistry Letters, 9
-
L. O’Brien, K. Tang, Ellen Kats, A. Schutz-Geschwender, J. Lipschutz, K. Mostov (2004)
ERK and MMPs sequentially regulate distinct stages of epithelial tubule development.Developmental cell, 7 1
-
Fichter (2006)
Collagen degradation products modulate matrix metalloproteinase expression in cultured articular chondrocytesJ Orthop Res, 24
-
J. Peterson (2006)
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.Cardiovascular research, 69 3
-
(2006)
Renal toxicity and hyperbilirubinemia of a novel matrix metalloproteinase (MMP) inhibitor in cynomolgus monkeys -
N. Johansson, K. Airola, R. Grénman, A. Kariniemi, U. Saarialho‐kere, V. Kähäri (1997)
Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck.The American journal of pathology, 151 2
-
M-P Graverand-Gastineau (2009)
OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?Osteoarthritis and cartilage, 17 11
-
R. Barve, J. Minnerly, D. Weiss, D. Meyer, D. Aguiar, P. Sullivan, S. Weinrich, R. Head (2007)
Transcriptional profiling and pathway analysis of monosodium iodoacetate-induced experimental osteoarthritis in rats: relevance to human disease.Osteoarthritis and cartilage, 15 10
-
L. Foley, R. Palermo, P. Dunten, P. Wang (2001)
Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.Bioorganic & medicinal chemistry letters, 11 8
-
L. Gooljarsingh, A. Lakdawala, Frank Coppo, L. Luo, G. Fields, P. Tummino, R. Gontarek (2007)
Characterization of an exosite binding inhibitor of matrix metalloproteinase 13Protein Science, 17
-
Hui-Jen Chang, Ming-Je Yang, Yu-Hsiang Yang, M. Hou, E. Hsueh, Shiu‐Ru Lin (2009)
MMP13 is potentially a new tumor marker for breast cancer diagnosis.Oncology reports, 22 5
-
M. Janusz, E. Hookfin, S. Heitmeyer, J. Woessner, A. Freemont, J. Hoyland, K. Brown, L. Hsieh, N. Almstead, Biswanath De, Natchus George, S. Pikul, Taiwo Olabisi (2001)
Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors.Osteoarthritis and cartilage, 9 8
-
M. Fichter, U. Körner, J. Schömburg, L. Jennings, A. Cole, J. Mollenhauer (2006)
Collagen degradation products modulate matrix metalloproteinase expression in cultured articular chondrocytesJournal of Orthopaedic Research, 24
-
R. Renkiewicz, Luping Qiu, C. Lesch, Xin-Xin Sun, R. Devalaraja, Theresa Cody, E. Kaldjian, H. Welgus, V. Baragi (2003)
Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats.Arthritis and rheumatism, 48 6
-
L. Reiter, J. Rizzi, J. Pandit, M. Lasut, S. McGahee, V. Parikh, J. Blake, D. Danley, E. Laird, A. Lopez-Anaya, L. Lopresti-Morrow, M. Mansour, G. Martinelli, P. Mitchell, B. Owens, T. Pauly, L. Reeves, G. Schulte, S. Yocum (1999)
Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.Bioorganic & medicinal chemistry letters, 9 2
-
T. Barta, D. Becker, L. Bedell, G. Crescenzo, J. McDonald, G. Munie, S. Rao, H. Shieh, R. Stegeman, A. Stevens, C. Villamil (2000)
Synthesis and activity of selective MMP inhibitors with an aryl backbone.Bioorganic & medicinal chemistry letters, 10 24
-
R. Billinghurst, L. Dahlberg, M. Ionescu, A. Reiner, R. Bourne, C. Rorabeck, Peter Mitchell, J. Hambor, O. Diekmann, H. Tschesche, Jeffrey Chen, H. Wart, A. Poole (1997)
Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage.The Journal of clinical investigation, 99 7
-
L. Neuhold, L. Killar, Weiguang Zhao, M. Sung., L. Warner, J. Kulik, James Turner, William Wu, C. Billinghurst, T. Meijers, A. Poole, P. Babij, L. Degennaro (2001)
Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice.The Journal of clinical investigation, 107 1
-
Yonghan Hu, J. Xiang, M. Digrandi, Xuemei Du, M. Ipek, L. Laakso, Jianchang Li, Wei Li, T. Rush, J. Schmid, J. Skotnicki, S. Tam, J. Thomason, Qin Wang, J. Levin (2005)
Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.Bioorganic & medicinal chemistry, 13 24
-
V. Aranapakam, J. Davis, G. Grosu, J. Baker, J. Ellingboe, A. Zask, J. Levin, V. Sandanayaka, M. Du, J. Skotnicki, J. Dijoseph, A. Sung, M. Sharr, L. Killar, T. Walter, G. Jin, R. Cowling, J. Tillett, Weiguang Zhao, J. Mcdevitt, Z. Xu (2003)
Synthesis and Structure−Activity Relationship of N-Substituted 4-Arylsulfonylpiperidine-4-hydroxamic Acids as Novel, Orally Active Matrix Metalloproteinase Inhibitors for the Treatment of OsteoarthritisJournal of Medicinal Chemistry, 46
-
W. Jencks (1981)
On the attribution and additivity of binding energies.Proceedings of the National Academy of Sciences of the United States of America, 78 7
-
J. Freskos (2010)
Discovery of a Novel Series of Selective MMP Inhibitors: Identification of the γ-Sulfone-thiols.ChemInform, 30
-
A. Klatt, Brigitte Paul‐Klausch, Gabriele Klinger, G. Kühn, J. Renno, Marc Banerjee, G. Malchau, K. Wielckens (2009)
A critical role for collagen II in cartilage matrix degradation: Collagen II induces pro‐inflammatory cytokines and MMPs in primary human chondrocytesJournal of Orthopaedic Research, 27
-
Rosa Hoekstra, F. Eskens, Jaap Verweij (2001)
Matrix metalloproteinase inhibitors: current developments and future perspectives.The oncologist, 6 5
-
C. Little, A. Barai, D. Burkhardt, Susan Smith, A. Fosang, Z. Werb, M. Shah, E. Thompson (2009)
Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development.Arthritis and rheumatism, 60 12
- Publisher
- Wiley
- Copyright
- © 2010 Wiley Periodicals, Inc.
- ISSN
- 0198-6325
- eISSN
- 1098-1128
- DOI
- 10.1002/med.20204
- pmid
- 20196103
- Publisher site
- See Article on Publisher Site
Abstract
Pharmacology of MMP13 and MMP13 selective inhibitors is reviewed. © 2010 Wiley Periodicals, Inc. Med Res Rev 31:863‐894, 2011
Journal
Medicinal Research Reviews – Wiley
Published: Nov 1, 2011